利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.03 秒)

    ANTI-FXI ANTIBODIES AND METHODS OF USE
    1.
    发明公开
    ANTI-FXI ANTIBODIES AND METHODS OF USE 审中-公开
    抗逆转录病毒感染者VERFAHREN ZU IHRER VERWENDUNG

    公开(公告)号：EP2373691A2

    公开(公告)日：2011-10-12

    申请号：EP09837993.6

    申请日：2009-12-18

    申请人： Oregon Health&Science University ,  Vanderbilt University ,  Gruber, Andras ,  Tucker, Erik I. ,  Gailani, David

    发明人： GRUBER, Andras ,  TUCKER, Erik, I. ,  GAILANI, David

    IPC分类号： C07K16/36 ,  C12N15/13 ,  A61K39/395 ,  A61P7/02

    CPC分类号： C07K16/36 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76

    摘要： Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.

    摘要翻译： 本文公开的是针对因子XI（fXI）特异的单克隆抗体，其阻止因子XIIa（fXIIa）激活fXI。 单克隆抗体是通用的fXI抗体，能够结合所有被检测的哺乳动物。 抗fXI单克隆抗体延长哺乳动物血浆中的凝血时间。 此外，本文公开的fXI单克隆抗体的施用导致血栓形成的抑制，而不改变血栓形成的动物模型中的止血。 因此，本文提供的是针对fXI特异性的阻断fXIIa的fXI活化的单克隆抗体，包含此类抗体的组合物和免疫缀合物及其使用方法。

    ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
    3.
    发明公开
    ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
    维多利亚·安东尼·维克多·维尔多·杜文

    公开(公告)号：EP3002298A1

    公开(公告)日：2016-04-06

    申请号：EP15189714.7

    申请日：2008-11-21

    申请人： Oregon Health & Science University ,  Vanderbilt University

    发明人： GRUBER, Andras ,  TUCKER, Erik, Ian ,  HANSON, Stephen, Raymond ,  GAILANI, David

    IPC分类号： C07K16/36 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

    CPC分类号： C07K16/36 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.

    摘要翻译： 本发明涉及在不危及止血的情况下抑制血栓形成的组合物和方法。 组合物包括能够结合人FXI重链上的表位的抗因子XI单克隆抗体（aXIMab），特别是人类FXI重链的A3结构域。 组合物还包括单克隆抗体的表位结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。 本发明还包括在药学上可接受的载体中包含本发明的抗因子XI单克隆抗体或其表位结合片段，变体或衍生物的药物组合物。 本发明的方法包括将上述组合物施用于有需要的受试者，以抑制血栓形成，减少治疗血栓形成，治疗转移性癌症或治疗急性炎症反应所需的抗血栓形成剂量。 还提供了制备抗因子XI单克隆抗体或表位结合片段，变体或其衍生物的方法。

    ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
    5.
    发明授权
    ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF 有权
    维多利亚·安东尼奥·安东尼奥·维克多·安德鲁

    公开(公告)号：EP2222707B1

    公开(公告)日：2016-01-06

    申请号：EP08852770.0

    申请日：2008-11-21

    申请人： Oregon Health & Science University ,  Vanderbilt University

    发明人： GRUBER, Andras ,  TUCKER, Erik, Ian ,  HANSON, Stephen, Raymond ,  GAILANI, David

    IPC分类号： C07K16/36 ,  A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/36 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2316/96 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.

    摘要翻译： 本发明涉及在不危及止血的情况下抑制血栓形成的组合物和方法。 组合物包括能够结合人FXI重链上的表位的抗因子XI单克隆抗体（aXIMab），特别是人类FXI重链的A3结构域。 组合物还包括单克隆抗体的表位结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。 本发明还包括在药学上可接受的载体中包含本发明的抗因子XI单克隆抗体或其表位结合片段，变体或衍生物的药物组合物。 本发明的方法包括将上述组合物施用于有需要的受试者，以抑制血栓形成，减少治疗血栓形成，治疗转移性癌症或治疗急性炎症反应所需的抗血栓形成剂量。 还提供了制备抗因子XI单克隆抗体或表位结合片段，变体或其衍生物的方法。